Literature DB >> 3346734

Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens.

D A Goodwin1, C F Meares, M J McCall, M McTigue, W Chaovapong.   

Abstract

A method of tumor imaging utilizing the nonspecific accumulation of antibody through leaky capillaries is described, in which the antibody and the radiolabel are administered separately. Nonradioactive antibody is given first (pre-targeted), and allowed adequate time to reach maximum tumor concentration. Depending on the antibody, this may take several days. At the time of maximum tumor concentration of nonradioactive antibody, the blood is quickly cleared of excess circulating nonradioactive antibody using a special i.v. "chase". The radiolabel then is given and imaging done in 1 to 3 hr. The use of short lived tracers (hours) to image antibodies that localize slowly (days) in-vivo is made possible by this method.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346734

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  43 in total

1.  Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.

Authors:  Kelly Davis Orcutt; Khaled A Nasr; David G Whitehead; John V Frangioni; K Dane Wittrup
Journal:  Mol Imaging Biol       Date:  2011-04       Impact factor: 3.488

2.  Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods?

Authors:  David M Goldenberg; Chien-Hsing Chang; Robert M Sharkey; Edmund A Rossi; Habibe Karacay; William McBride; Hans J Hansen; Jean-Francois Chatal; Jacques Barbet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-06       Impact factor: 9.236

3.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

Review 4.  Molecular imaging perspectives.

Authors:  Paul J Cassidy; George K Radda
Journal:  J R Soc Interface       Date:  2005-06-22       Impact factor: 4.118

Review 5.  Does immunoscintigraphy serve clinical needs effectively? Is there a future for radioimmunotherapy?

Authors:  J F Chatal; P Peltier; M Bardiès; A Chétanneau; P Thedrez; A Faivre-Chauvet; J F Gestin
Journal:  Eur J Nucl Med       Date:  1992

6.  A modular IgG-scFv bispecific antibody topology.

Authors:  Kelly Davis Orcutt; Margaret E Ackerman; Maryelise Cieslewicz; Emmanuel Quiroz; Adrian L Slusarczyk; John V Frangioni; K Dane Wittrup
Journal:  Protein Eng Des Sel       Date:  2009-12-17       Impact factor: 1.650

7.  6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors:  Alain Beck; Thierry Wurch; Janice M Reichert
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

8.  Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.

Authors:  Guozheng Liu; Shuping Dou; Xiangji Chen; Ling Chen; Xinrong Liu; Mary Rusckowski; Donald J Hnatowich
Journal:  Cancer Biother Radiopharm       Date:  2010-12       Impact factor: 3.099

Review 9.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

Review 10.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.